Lonafarnib b: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

29 April 2025

  • curprev 20:4220:42, 29 April 2025 Alara E. Dagsali talk contribs 22,253 bytes +22,253 Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=lonafarnib |aOrAn=a |drugClass=direct farnesyl transferase inhibitor |indication=ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: *To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) *For the treatment of processing-deficient Progeroid Laminopathies with either: - Heterozygous LMNA mut..."
Retrieved from "https://www.wikidoc.org/index.php/Lonafarnib_b"